{"id":36672,"date":"2025-10-22T15:06:22","date_gmt":"2025-10-22T08:06:22","guid":{"rendered":"https:\/\/thaipropertynews.com\/feeds\/?p=36672"},"modified":"2025-10-22T15:06:22","modified_gmt":"2025-10-22T08:06:22","slug":"liscure-biosciences-secures-worlds-first-approval-for-joint-health-probiotic-as-recognized-health-functional-ingredient","status":"publish","type":"post","link":"https:\/\/thaipropertynews.com\/feeds\/?p=36672","title":{"rendered":"LISCure BioSciences Secures World&#8217;s First Approval for &#8220;Joint Health Probiotic&#8221; as Recognized Health Functional Ingredient"},"content":{"rendered":"<p><span class=\"legendSpanClass\"><span class=\"xn-location\">SEOUL, South Korea<\/span><\/span>, <span class=\"legendSpanClass\"><span class=\"xn-chron\">Oct. 22, 2025<\/span><\/span> \/PRNewswire\/ &#8212; LISCure BioSciences (&#8220;LISCure&#8221;) announced that its proprietary joint health probiotic, JointWorks\u00ae, has been officially approved by the Korean Ministry of Food and Drug Safety (MFDS) as Recognized Health Functional Ingredient.<\/p>\n<p>This approval marks a historic milestone \u2014 JointWorks<sup>\u00ae<\/sup> \u00a0is the world&#8217;s first probiotic clinically proven to support joint health\u00a0and remains the only\u00a0probiotic ingredient approved by the MFDS for joint functionality.<\/p>\n<p>Breakthrough in Joint Health Innovation<\/p>\n<p>Developed exclusively by LISCure, JointWorks<sup>\u00ae<\/sup> represents a paradigm shift in the joint health market, which has long been dominated by natural extracts. By introducing a new functional probiotic ingredient, LISCure is expected to play a pivotal role in driving innovation and growth in the category.<\/p>\n<p>In a 12-week clinical study, JointWorks<sup>\u00ae<\/sup> demonstrated statistically significant improvements (<i>p<\/i>&lt;0.05, 95% confidence level) across multiple indicators of joint health, including:<\/p>\n<ul type=\"disc\">\n<li>Total WOMAC score (pain, stiffness, and physical function)<\/li>\n<li>Visual Analogue Scale (VAS) score \u00a0<\/li>\n<li>Quality of life assessment (EQ-5D-5L)<\/li>\n<li>Reduction of inflammatory cytokines related to joint function and pain<\/li>\n<\/ul>\n<p>Further preclinical and clinical studies confirmed JointWorks<sup>\u00ae<\/sup> mechanisms of action \u2014 including joint and cartilage protection, inflammation suppression, pain reduction, and cartilage cell preservation \u2014 validating its scientific foundation.<\/p>\n<p>Participants also reported notable improvement in daily joint function and quality of life.<\/p>\n<p>With these differentiated benefits, JointWorks<sup>\u00ae<\/sup> is being recognized as a next-generation &#8220;Healthcare Probiotic.&#8221;<\/p>\n<p>Key preclinical and clinical data have been published in peer-reviewed journals, including <i>J. Microbiol. Biotechnol.<\/i> (MK Song <i>et al<\/i>) and <i><a href=\"https:\/\/www.nature.com\/srep\" target=\"_blank\" rel=\"nofollow\">Scientific Reports<\/a> <\/i>(<a href=\"https:\/\/www.nature.com\/articles\/s41598-025-11250-0#auth-Bo_Kyung-Shine-Aff1\" target=\"_blank\" rel=\"nofollow\">BK Shine<\/a>. MD. <i>et al<\/i>), providing strong scientific validation.<\/p>\n<p>Expanding Market and Growing Demand<\/p>\n<p>Korea&#8217;s joint health functional food market is valued at approximately <span class=\"xn-money\">KRW 480 billion<\/span> (<span class=\"xn-money\">USD 350 million<\/span>), making it the third-largest segment in the domestic health supplement industry, following probiotics and multivitamins.<\/p>\n<p>The rise of &#8220;active seniors&#8221; and an aging population committed to wellness and preventive care is fueling demand for new, science-backed joint health solutions.<\/p>\n<p><b>Executive Commentary<\/b><\/p>\n<p>&#8220;The MFDS approval of JointWorks<sup>\u00ae<\/sup> goes beyond functional validation \u2014 it signifies the expansion of probiotics into a new category: joint health,&#8221; said <span class=\"xn-person\">Jae-Seok Shim<\/span>, Vice President of LISCure.<\/p>\n<p>&#8220;This achievement strengthens our position not only in Korea but also in the global\u00a0nutraceutical market.&#8221; he added.<\/p>\n<p>&#8220;Following the MFDS approval of our hair-health probiotic ingredient Mobiome<sup>\u00ae<\/sup> earlier this year, JointWorks<sup>\u00ae<\/sup> marks our secondary regulatory milestone, reaffirming LISCure&#8217;s pioneering position in next-generation probiotics.&#8221;<\/p>\n<p>LISCure is developing next-generation probiotics that go beyond gut health \u2013 supporting systemic benefits in areas such as joint, kidney, cognitive and metabolic health.<\/p>\n<p>He added, &#8220;With a commitment to evidence-based R&amp;D, LISCure will continue developing next-generation probiotics targeting systemic health and accelerating collaborations with global partners across <span class=\"xn-location\">North America<\/span>, <span class=\"xn-location\">Europe<\/span>, and <span class=\"xn-location\">Southeast Asia<\/span>.&#8221;<\/p>\n<p><b>Upcoming Global Showcase at SupplySide Global 2025<\/b><\/p>\n<p>LISCure will present JointWorks<sup>\u00ae<\/sup> and Mobiome<sup>\u00ae<\/sup> \u2014 both approved by the MFDS \u2014 at SupplySide Global 2025 in <b><span class=\"xn-location\">Las Vegas<\/span><\/b> next week, the world&#8217;s largest food ingredient exhibition.<\/p>\n<p>The company will also highlight its expanding portfolio focused on kidney health, weight management, and blood sugar regulation and ongoing U.S. FDA NDI notification and global partnerships.<\/p>\n<p>Advancing Drug Development Pipeline<\/p>\n<p>In parallel with its nutraceutical business, LISCure continues to advance its core biopharmaceutical programs, including:<\/p>\n<ul type=\"disc\">\n<li>Technology transfer of BBB-shuttle platform ExoPN-101<\/li>\n<li>U.S. Phase II clinical trial of liver disease treatment LB-P8, designated as Orphan Drug (ODD) and Fast Track by the U.S. FDA<\/li>\n<li>U.S. clinical entry of anti-cancer candidate LB-P2D, which demonstrated strong efficacy in preclinical studies<\/li>\n<\/ul>\n<p>LISCure aims to secure sustainable growth by balancing innovation-driven drug development with stable revenue generation from its functional health ingredient business.<\/p>\n<p>\u00a0<\/p>","protected":false},"excerpt":{"rendered":"<p><!-- wp:html --><\/p>\n<p><span class=\"legendSpanClass\"><span class=\"xn-location\">SEOUL, South Korea<\/span><\/span>, <span class=\"legendSpanClass\"><span class=\"xn-chron\">Oct. 22, 2025<\/span><\/span> \/PRNewswire\/ &#8212; LISCure BioSciences (&#8220;LISCure&#8221;) announced that its proprietary joint health probiotic, JointWorks\u00ae, has been officially approved by the Korean Ministry of Food and Drug Safety (MFDS) as Recognized Health Functional Ingredient.<\/p>\n<p>This approval marks a historic milestone \u2014 JointWorks<sup>\u00ae<\/sup> \u00a0is the world&#8217;s first probiotic clinically proven to support joint health\u00a0and remains the only\u00a0probiotic ingredient approved by the MFDS for joint functionality.<\/p>\n<p>Breakthrough in Joint Health Innovation<\/p>\n<p>Developed exclusively by LISCure, JointWorks<sup>\u00ae<\/sup> represents a paradigm shift in the joint health market, which has long been dominated by natural extracts. By introducing a new functional probiotic ingredient, LISCure is expected to play a pivotal role in driving innovation and growth in the category.<\/p>\n<p>In a 12-week clinical study, JointWorks<sup>\u00ae<\/sup> demonstrated statistically significant improvements (<i>p<\/i>&lt;0.05, 95% confidence level) across multiple indicators of joint health, including:<\/p>\n<ul type=\"disc\">\n<li>Total WOMAC score (pain, stiffness, and physical function)<\/li>\n<li>Visual Analogue Scale (VAS) score \u00a0<\/li>\n<li>Quality of life assessment (EQ-5D-5L)<\/li>\n<li>Reduction of inflammatory cytokines related to joint function and pain<\/li>\n<\/ul>\n<p>Further preclinical and clinical studies confirmed JointWorks<sup>\u00ae<\/sup> mechanisms of action \u2014 including joint and cartilage protection, inflammation suppression, pain reduction, and cartilage cell preservation \u2014 validating its scientific foundation.<\/p>\n<p>Participants also reported notable improvement in daily joint function and quality of life.<\/p>\n<p>With these differentiated benefits, JointWorks<sup>\u00ae<\/sup> is being recognized as a next-generation &#8220;Healthcare Probiotic.&#8221;<\/p>\n<p>Key preclinical and clinical data have been published in peer-reviewed journals, including <i>J. Microbiol. Biotechnol.<\/i> (MK Song <i>et al<\/i>) and <i><a href=\"https:\/\/www.nature.com\/srep\" target=\"_blank\" rel=\"nofollow\">Scientific Reports<\/a> <\/i>(<a href=\"https:\/\/www.nature.com\/articles\/s41598-025-11250-0#auth-Bo_Kyung-Shine-Aff1\" target=\"_blank\" rel=\"nofollow\">BK Shine<\/a>. MD. <i>et al<\/i>), providing strong scientific validation.<\/p>\n<p>Expanding Market and Growing Demand<\/p>\n<p>Korea&#8217;s joint health functional food market is valued at approximately <span class=\"xn-money\">KRW 480 billion<\/span> (<span class=\"xn-money\">USD 350 million<\/span>), making it the third-largest segment in the domestic health supplement industry, following probiotics and multivitamins.<\/p>\n<p>The rise of &#8220;active seniors&#8221; and an aging population committed to wellness and preventive care is fueling demand for new, science-backed joint health solutions.<\/p>\n<p><b>Executive Commentary<\/b><\/p>\n<p>&#8220;The MFDS approval of JointWorks<sup>\u00ae<\/sup> goes beyond functional validation \u2014 it signifies the expansion of probiotics into a new category: joint health,&#8221; said <span class=\"xn-person\">Jae-Seok Shim<\/span>, Vice President of LISCure.<\/p>\n<p>&#8220;This achievement strengthens our position not only in Korea but also in the global\u00a0nutraceutical market.&#8221; he added.<\/p>\n<p>&#8220;Following the MFDS approval of our hair-health probiotic ingredient Mobiome<sup>\u00ae<\/sup> earlier this year, JointWorks<sup>\u00ae<\/sup> marks our secondary regulatory milestone, reaffirming LISCure&#8217;s pioneering position in next-generation probiotics.&#8221;<\/p>\n<p>LISCure is developing next-generation probiotics that go beyond gut health \u2013 supporting systemic benefits in areas such as joint, kidney, cognitive and metabolic health.<\/p>\n<p>He added, &#8220;With a commitment to evidence-based R&amp;D, LISCure will continue developing next-generation probiotics targeting systemic health and accelerating collaborations with global partners across <span class=\"xn-location\">North America<\/span>, <span class=\"xn-location\">Europe<\/span>, and <span class=\"xn-location\">Southeast Asia<\/span>.&#8221;<\/p>\n<p><b>Upcoming Global Showcase at SupplySide Global 2025<\/b><\/p>\n<p>LISCure will present JointWorks<sup>\u00ae<\/sup> and Mobiome<sup>\u00ae<\/sup> \u2014 both approved by the MFDS \u2014 at SupplySide Global 2025 in <b><span class=\"xn-location\">Las Vegas<\/span><\/b> next week, the world&#8217;s largest food ingredient exhibition.<\/p>\n<p>The company will also highlight its expanding portfolio focused on kidney health, weight management, and blood sugar regulation and ongoing U.S. FDA NDI notification and global partnerships.<\/p>\n<p>Advancing Drug Development Pipeline<\/p>\n<p>In parallel with its nutraceutical business, LISCure continues to advance its core biopharmaceutical programs, including:<\/p>\n<ul type=\"disc\">\n<li>Technology transfer of BBB-shuttle platform ExoPN-101<\/li>\n<li>U.S. Phase II clinical trial of liver disease treatment LB-P8, designated as Orphan Drug (ODD) and Fast Track by the U.S. FDA<\/li>\n<li>U.S. clinical entry of anti-cancer candidate LB-P2D, which demonstrated strong efficacy in preclinical studies<\/li>\n<\/ul>\n<p>LISCure aims to secure sustainable growth by balancing innovation-driven drug development with stable revenue generation from its functional health ingredient business.<\/p>\n<p>\u00a0<\/p>\n<p><!-- \/wp:html --><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"rop_custom_images_group":[],"rop_custom_messages_group":[],"rop_publish_now":"initial","rop_publish_now_accounts":[],"rop_publish_now_history":[],"rop_publish_now_status":"pending","footnotes":""},"categories":[5,7],"tags":[],"class_list":["post-36672","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-cision-pr-newswire","category-cision-pr-newswire-en"],"_links":{"self":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/posts\/36672","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=36672"}],"version-history":[{"count":0,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/posts\/36672\/revisions"}],"wp:attachment":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=36672"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=36672"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=36672"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}